⚡ Gain the edge in oncology drug development. While others face delays, Champions helps you accelerate from CDX → PDX with a seamless progression. The result: faster insights, stronger confidence in your data, and the ability to make decisions before the competition. When every week counts, speed isn’t just an advantage, it’s the difference between leading and catching up. Our goal is simple: help you move faster, without unnecessary delays holding you back. 👉 Select Your model https://hubs.li/Q03L4YRp0 Talk to an ccount manager today to learn how we help you outpace the rest.https://hubs.li/Q03L4Y1b0 👉 #OncologyResearch #PreclinicalModels #DrugDevelopment #CDX #PDX #ChampionsOncology
Champions Oncology, Inc.
Biotechnology
Hackensack, New Jersey 10,776 followers
US-based, End-to-End Oncology Pharmacology Solutions CRO
About us
Champions Oncology, Inc. provides an end-to-end range of research and development solutions and services that improve the productivity of oncology drug development. Using both in vitro to in vivo testing platforms companies can leverage the expertise at Champions Oncology to help guide decision making for clinical development scenarios. From screens using commercially-available and custom cell lines, to studies leveraging syngeneic or traditional patient-derived studies xenograft (PDX) models, and modeling treatment response in the clinic, Champions Oncology is your partner in meeting today’s needs and innovating for tomorrow’s challenges. At the core of our services is the Champions TumorGraft® (CTG) platform, a comprehensive, unique compendium of PDX models that preserve the biological characteristics of human tumors and are highly predictive of clinical outcomes. Services utilizing Champions TumorGrafts® PDX tumor models include evaluating tumor sensitivity/resistance to various single, combination, standard and novel chemotherapy agents, biomarker discovery and the identification of novel drug combinations. Champions TumorGraft® PDX models are procured through agreements our Clinical Collaboration Network, a series of renowned oncology institutions in the US and around the world, as well as through the company’s Personalized Oncology Solutions business. Personalized Oncology Solutions assist clinical oncologists by establishing and administering expert tumor panels for their patients to analyze medical records and test results, to assist in understanding conventional and experimental options and to identify and arrange for testing, analysis and study of the patients’ cancer tissues, as appropriate. Additionally, the company offers personalized PDX development, drug studies and genome sequencing, whereby physicians evaluate the effects of cancer drugs and understand the genetic makeup of each patient’s tumor, enabling them to better select treatment regimens.
- Website
-
http://www.championsoncology.com
External link for Champions Oncology, Inc.
- Industry
- Biotechnology
- Company size
- 201-500 employees
- Headquarters
- Hackensack, New Jersey
- Type
- Public Company
- Founded
- 2007
- Specialties
- Translational Oncology Research, Personalized Oncology, Patient Derived Xenograft, Oncology Pharmacology, Immuno-Oncology, Flow Cytometry, Syngeneic Models, Humanized Mouse Models, Clinical Flow Cytometry, PDX, 3D Organoid Models, Clinical Specialty Testing, Hematological Modeling, Leukemia Models, GCLP, Cancer Vaccine Research, Preclinical Oncology Research, Global Clinical Trials, Ex Vivo Platforms, CDX, Cell Line Screening, Organoid Screening, Orthotopic Modeling, Computational Biology, Bioinformatics, Proteomics, and Multi-Omics
Locations
-
Primary
Get directions
Hackensack
Hackensack, New Jersey 07601, US
-
Get directions
1330 Piccard Dr
Suite 025 & 104
Rockville, Maryland 20850, US
-
Get directions
Via L. Ariosto 21, 1st Floor
Bresso MI, 20091, IT
-
Get directions
4 Oppenheimer St., Ha’ogen Building B
Rehovot, 7670104, IL
Employees at Champions Oncology, Inc.
-
Scott Tobin
Senior Partner at Battery Ventures
-
Christine Baer
Senior Laboratory Manager | NGS & Formulations Expert | Genomics | Assay Development | CLIA/CAP/GCLP | Team Leadership | Tech Transfer | Lab Ops…
-
Rob Brainin
Life Sciences and Healthcare C-Suite Executive and Board Director
-
Brady Davis
Updates
-
We're #hiring a new Product Manager in United States. Apply today or share this post with your network.
-
We're #hiring a new Key Account Manager in United States. Apply today or share this post with your network.
-
🚀 Enrollment is now open for Champions Oncology’s SSTR2 Radiopharmaceutical In Vivo Screen. 👉https://hubs.li/Q03Jn1pg0 This curated panel of 35 patient-derived xenograft (PDX) models includes neuroendocrine tumors, Merkel cell carcinoma, and select SCLC models with confirmed SSTR2 expression. Backed by our integrated radiochemistry and radiopharmacology capabilities, this screen delivers translationally meaningful insights for both therapeutic and theranostic programs. 🔑 Why it matters: - The only CRO with in-house radiochemistry + radiopharmacology - Clinically relevant, diverse tumor models - Clear, actionable TGI readouts Enrollment runs until October 31, 2025. Spots are limited. 👉 SSTR2 Radiopharmaceutical Screen https://hubs.li/Q03Jn1pg0 #Radiopharmaceuticals #OncologyResearch #TranslationalOncology #DrugDevelopment #PDXModels
-
-
Meet us at BioTechX USA: https://hubs.li/Q03HzSlg0 🤯Two Talks. One Data Ecosystem. One Mission Matt Newman | 12:45, Sept 16 | How Champions & Manifold are Shaping the AI Era of Oncology Drug Development Mike Ritchie |15:30, Sept 16 |Unlocking the Cell Surface: Translating Biology into Drug Discovery Advantage 📍 Philadelphia | BioTechX USA | September 16–17, 2025 ➡️ Schedule a meeting with our team to discover how our data ecosystem can accelerate your oncology programs. https://hubs.li/Q03HzSlg0 #BioTechXUSA #OncologyInnovation #CellSurfaceProteomics #OncologyResearch #AIinOncology #MultiOmics
-
-
AI in oncology isn’t about hype — it’s about the data that fuels it. Join Matt Newman at BioTechX USA as he explores how Champions Oncology & Manifold are shaping the AI era of oncology drug development. ➡️ Learn how patient-derived datasets are unlocking discovery and translational insights ➡️ See why integrated, multi-omic data is redefining the standard for AI-driven research 📍 Philadelphia | BioTechX USA |September 16, 2025 | 12:45 Schedule time with our team to discuss how our data ecosystem can support your next discovery program. https://hubs.li/Q03HzKJr0
-
-
The cell surface holds the keys to next-gen oncology drug discovery. At BioTechX USA, Mike Ritchie will reveal how Champions Oncology is translating cell surface biology into actionable drug discovery advantages. ➡️Explore the role of surface proteomics in target discovery ➡️Understand how deep patient-derived datasets provide unmatched translational relevance 📍 Philadelphia | BioTechX USA | September 16, 2025 | 15:30 Meet us at BioTechX USA: to dive deeper into our data ecosystem and explore collaboration opportunities. https://hubs.li/Q03HzDRs0 #CellSurfaceBiology #DrugDiscovery #OncologyResearch #Proteomics #TranslationalScience
-
-
👉Latest Post: Radiopharmaceutical Efficacy Studies in PDX Models: Why Tumor Diversity Matters: https://hubs.li/Q03HY5yj0 Radiopharmaceutical development hinges on data that reflects patient reality. PDX models preserve the heterogeneity of human tumors, capturing the antigen density, radiosensitivity, and biological complexity that shape real-world efficacy. By testing across diverse PDX panels, you can uncover which tumors respond, optimize dose strategies, and identify biomarker correlations earlier. The result: more reliable data, stronger IND packages, and improved clinical trial design. 👉 Read the post: https://hubs.li/Q03HY5yj0 ____________________________________ PDX Models + Radiopharmaceuticals = Translational Power: Champions Oncology is the only CRO pairing radiopharmaceutical studies with PDX tumor diversity to deliver data that truly translates to the clinic. 🔗 Explore our full capabilities: https://hubs.li/Q03HY6kW0
-
-
Watch now: 👉https://hubs.li/Q03HB8Kz0 Radiotracers and ADC Targeting: Scientific Insights for In Vivo Validation and Clinical Transition Radiotracers are becoming an essential tool for ADC developers, not just for imaging, but for real-time insight into ligand behavior, off-target uptake, and translational decision-making. In this webinar, you’ll learn: ✅ How to use radiolabeling to de-risk ADC development ✅ What makes a strong candidate for imaging and dosimetry ✅ How Champions Oncology’s PDX-based workflow supports faster IND readiness ✅ Real examples of how biodistribution data is shaping go, no-go decisions 🎙️Speakers: 🔬 Dr. Shankar Vallabhajosula, Weill Cornell, global authority in radiopharmaceuticals 🔬 Dr. Denis Beckford-Vera, Champions Oncology, expert in radiotracer study design 👉https://hubs.li/Q03HB8Kz0
-
-
Meet us at BioTechX USA: https://hubs.li/Q03HzClG0 Two Talks. One Data Ecosystem. Infinite Possibilities. Champions Oncology is advancing oncology drug development with patient-derived, multi-omic, and functional data that powers AI and translational research. Matt Newman | 12:45, Sept 16 | How Champions & Manifold are Shaping the AI Era of Oncology Drug Development Mike Ritchie |15:30, Sept 16 |Unlocking the Cell Surface: Translating Biology into Drug Discovery Advantage 📍 Philadelphia | September 16–17, 2025 ➡️ Schedule a meeting with our team to discover how our data ecosystem can accelerate your oncology programs. https://hubs.li/Q03HzClG0 #BioTechXUSA #OncologyInnovation #CellSurfaceProteomics #OncologyResearch #AIinOncology #MultiOmics
-